FDA Determines Regulatory Review Period for SYMLIN Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for SYMLIN, a human drug product, in accordance with patent extension regulations, following a submission to the US Department of Commerce.